# Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI

> **NCT07132489** · — · NOT_YET_RECRUITING · sponsor: **Assiut University** · enrollment: 114 (estimated)

## Conditions studied

- Myocardial Infarction
- No Reflow Phenomenon

## Interventions

- **DIAGNOSTIC_TEST:** HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio

## Key facts

- **NCT ID:** NCT07132489
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2028-09-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07132489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07132489, "Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07132489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*